Table 3 Comparison of objective pain measures and oxidative stress markers between FMS Sham-rTMS and Real-rTMS group
| Â | Pre-rTMS | Post-rTMS | Follow-up |
|---|---|---|---|
FU-1 (15-days) | |||
NFR: Latency (ms) | |||
 Sham | 105.0 (95.0–124.4) | 105.0 (90.0–120.0) | 102.0 (87.6–104.0) |
 Real | 110.0 (95.5–137.8) | 106.5 (97.6–120.8) | 105.0 (97.3–120.0) |
 p* | 0.41 | 0.06 | 0.05 |
NFR: Duration (ms) | |||
 Sham | 42.5 (40.0–47.5) | 42.5 (40.0–45.5) | 45.0 (40.0–50.0) |
 Real | 40.5 (38.3–45.25) | 40.0 (38.65–45.0) | 42.3 (40.0–45.0) |
 p* | 0.52 | 0.06 | 0.07 |
NFR: Amplitude ((μV) | |||
 Sham | 294.0 (273.0–312.0) | 287.0 (263.3–297.0) | 284.5 (260.8–298.5) |
 Real | 281.6 (260.5 ± 314.3) | 276.0 (234.5–311.5) | 276.0 (243.8–295.2) |
 p* | 0.42 | 0.28 | 0.35 |
DNIC: Threshold (V) | |||
 Sham | 21.0 (18.5–24.5) | 21.0 (20.0–24.0) | 22.0 (19.0–25.0) |
 Real | 22.0 (18.0–25.5) | 27.0 (25.0–34.0) ## | 29.0 (25.0–39.0) |
 p* | 0.75 | 0.001 | 0.001 |
Thiobarbituric acid reactive substances; TBARS (ng/ml) | |||
 Sham | 0.88 (0.11–2.3) | 0.90 (0.22–2.11) | – |
 Real | 0.97 (0.23–2.1) | 0.78 (0.18–1.6) | – |
 p* | 0.71 | 0.07 | – |
F2-isoprostanes (pg/ml) | |||
 Sham | 209.8 (135.8–317.4) | 183.9 (123.6–251.4) | – |
 Real | 180.4 (78.35–243.8) | 181.9 (89.4–315.3) | – |
 p* | 0.14 | 0.19 | – |